Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.03 | N/A | -62.66% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-2.03 | N/A | -62.66% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions affecting performance. They did not offer specific guidance for future quarters.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in meeting market expectations.
Ultragenyx Pharma's first-quarter earnings report revealed a significant miss on EPS, which contributed to a 4.38% decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term outlook. Management's defensive tone suggests they are facing challenges in the current market environment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENTERPRISE PRODS PAR